All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.68 [0.22; 2.08]
NCT04422561 (Shouman), 2020 0.50 [0.01; 25.20]
0.66 [0.23 ; 1.94 ] BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, NCT04422561 (Shouman), 2020 2 0% 2,801 moderate not evaluable new illness compatible with Covid-19 detailed results NCT04422561 (Shouman), 2020 0.06 [0.03; 0.11]
0.06 [0.03 ; 0.11 ] NCT04422561 (Shouman), 2020 1 0% 304 NA not evaluable infection (PCR positive symptomatic or not)detailed results BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.86 [0.52; 1.42]
0.86 [0.52 ; 1.42 ] BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 1 0% NA not evaluable serious adverse eventsdetailed results BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.89 [0.44; 1.82]
NCT04422561 (Shouman), 2020 0.50 [0.01; 25.20]
0.88 [0.44 ; 1.77 ] BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, NCT04422561 (Shouman), 2020 2 0% 2,801 moderate not evaluable adverse eventsdetailed results Out of scale BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 20.26 [15.67; 26.20]
NCT04422561 (Shouman), 2020 11.52 [0.67; 197.97]
20.17 [15.61 ; 26.05 ] BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, NCT04422561 (Shouman), 2020 2 0% 2,801 moderate not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-05 04:20 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 89
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290